Single Source for Continuation of the Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal (U01 Research Project (Cooperative Agreement) Clinical Trial not allowed)

HHS-NIH11 RFA-DK-26-313
Posted: Feb 06, 2026 12:00:00 AM EST
Closes: 03/10/2026

Funding Information

Award Ceiling
$2,000,000
Expected Number of Awards
1

Description

This non-competitive Notice of Funding Opportunity (NOFO) is intended to fund a single award to the current awardee institution of the Accelerating Medicines Partnership in Common Metabolic Diseases Knowledge Portal (AMP CMD KP), the Broad Institute, Inc. The AMP CMD program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time NOFO to provide funds to the AMP CMD KP to continue the development and maintenance of the web portal and underlying, curated knowledge base; which serves as the flagship resource encompassing the myriad types of data and information that provide an understanding of the biological heterogeneity in patients with CMDs and their related complications. In its next five-year period, the AMP CMD KP will be expected to continue its expansion of its datasets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base, and to develop a framework for independent sustainability. The application will be peer-reviewed and if it is not a meritorious application, it will not be funded.

Synopsis

This non-competitive Notice of Funding Opportunity (NOFO) is intended to fund a single award to the current awardee institution of the Accelerating Medicines Partnership in Common Metabolic Diseases Knowledge Portal (AMP CMD KP), the Broad Institute, Inc. The AMP CMD program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time NOFO to provide funds to the AMP CMD KP to continue the development and maintenance of the web portal and underlying, curated knowledge base; which serves as the flagship resource encompassing the myriad types of data and information that provide an understanding of the biological heterogeneity in patients with CMDs and their related complications. In its next five-year period, the AMP CMD KP will be expected to continue its expansion of its datasets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base, and to develop a framework for independent sustainability. The application will be peer-reviewed and if it is not a meritorious application, it will not be funded.

Eligibility

Eligible Applicants:
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Only the following applicant is eligible to apply for this single source funding: The Broad Institute, Inc. Please refer to Section I. Notice of Funding Opportunity Information for more details.

Funding Activity Categories

Health

CFDA Numbers

  • 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research

Contact Information

Agency: National Institutes of Health
Contact: National Institutes of Health
Phone: 301-402-2541
Division of Diabetes, Endocrinology and Metabolic Diseases
NIDDK_DEM@nih.gov

Additional Information

Document Type: synopsis
Opportunity Category: Discretionary
Version: 1
Last Updated: Feb 06, 2026 10:39:01 AM EST

Related Opportunities